It's Sept 1st. Trials often take longer than anticipated to fully enroll. I wouldn't get too nervous yet but I'm not you. The CIC Phase 3 results were later than most here predicted.
From ClinicalTrials.gov (last updated June 2015):
Estimated Enrollment: 1050
Study Start Date: December 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome
The study completion date is Dec 2015. The company has said the topline data will be forthcoming late 2015/ early 2016. I have no reason to doubt them.
"China has unleashed an unprecedented package of support measures, including using state-backed entities to buy stocks and cracking down on "malicious" short-selling -- when investors sell shares they do not own in anticipation of a fall in their price."
Analyst Timothy Chiang said, "We think SGYP’s plecanatide shows promise as a future treatment for CIC and IBS-C, which is a growing market category in the US. With ~45 million Americans suffering from chronic constipation and IBS, and companies like Allergan (AGN, Not Rated) and Valeant (VRX, Buy, $290 PT) focusing their marketing efforts on GI treatments, it seems logical to imagine SGYP as a takeover candidate."
It's no excuse for my stupid post this morning but one of my stocks is green today. EXEL is up over 6%. I'm not telling anyone to buy it - I have no idea why it's going up.
Sorry about the really bad post.
Sorry about that. I looked at two of my bios before posting. One wasn't trading and the other was green.
It was obviously a stupid post on my part.
If someone would've sold their stock and we're looking to repurchase, I would think they might want to wait till either the stock goes down to like 5.50 (possible if the market continues to tank) or wait till around November to start buying. The IBS-C results aren't due till the end of this year or early next year and (baring a partnership or buyout) the stock the stock might not go up significantly till then.
The Food and Drug Administration Amendments Act requires sponsors of applicable clinical trials to report findings to ClinicalTrials.gov within one year of completion. I don't believe there are requirements to publicly disclose trial results.
The top line results are the primary end points of the trial. More complete disclosure of trial results including secondary end points and additional analysis of the data are often presented at conferences and published in medical journals.
I have no idea what "internal results" refers to.
A few biotech stocks managed to buck the trend today, but most of them still finished down for the week.
"We're pinned at $7 for options expiration..."
Kindly correct me if I'm wrong but isn't the August maximum pain for this stock 8?
Why would the stock be "pinned" at 7 when the max pain is 8?
Have you noticed the whole market is getting beat up?
Even without the shorts, this stock would be trading lower.
I would suggest people stop calling the CEO an idiot. It reflects badly on your character.
From all appearances, they are doing their best to maximize shareholder value. If that means going it alone for now, so be it.
On July 8, 2015, we announced the appointment of Troy Hamilton as our Chief Commercial Officer. Mr. Hamilton will be responsible for our overall commercial strategy and execution, and will implement marketing, sales, and commercial operations and infrastructure for the U.S. launch of plecanatide. Mr. Hamilton has over 19 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Prior to joining us, Mr. Hamilton held multiple commercial leadership roles over a nine year period within Shire Pharmaceuticals' GI Business Unit.
We'll, I really screwed up this trade. Sold most of my shares today. Still ended up with a decent six figure gain.
I held on thinking they should get an acceptable offer in light of the great phase 3 results.
I'll start buying back if it goes to around 6-6.50.